Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer

SET is an endogenous PP2A inhibitor that might represent a novel molecular target for antitumor therapy. The aim of this study was to evaluate the molecular effects of SET deregulation and its potential clinical significance in metastatic colorectal cancer (mCRC). We studied the biologic effects of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2015-01, Vol.21 (2), p.347-356
Hauptverfasser:	Cristóbal, Ion, Rincón, Raúl, Manso, Rebeca, Caramés, Cristina, Zazo, Sandra, Madoz-Gúrpide, Juan, Rojo, Federico, García-Foncillas, Jesús
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cell Line, Tumor Colorectal Neoplasms - drug therapy Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Disease-Free Survival Drug Resistance, Neoplasm Female Gene Expression Histone Chaperones - physiology Humans Inhibitory Concentration 50 Kaplan-Meier Estimate Liver Neoplasms - drug therapy Liver Neoplasms - metabolism Liver Neoplasms - mortality Liver Neoplasms - secondary Male Middle Aged Molecular Targeted Therapy Organoplatinum Compounds - pharmacology Organoplatinum Compounds - therapeutic use Proportional Hazards Models Protein Phosphatase 2 - metabolism Retrospective Studies Transcription Factors - physiology Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!